American College of Rheumatology issues position statement on pharmacovigilance


(American College of Rheumatology) The American College of Rheumatology has released a position statement on pharmacovigilance emphasizing the need for the continued monitoring of new drugs once they are introduced to the market. As new medications like biosimilars are developed and approved for the treatment of rheumatic diseases, the ACR acknowledges the need for detecting and reporting adverse events, by both clinicians and patients.

Leave A Reply

Your email address will not be published.